COM:LYELL

Lyell Immunopharma, Inc.

Stock

Last Close

0.92

22/11 21:00

Market Cap

402.80M

Beta: -

Volume Today

1.01M

Avg: -

Overview Analysis Metrics Financials Filings people API Chart Data

Income Statement Balance Sheet Cash Flow Key Metrics Ratios

Quarterly

Yearly

Preview

Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page

Subscribe Now Help

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-129.38M -	-204.47M 58.04%	-250.22M 22.37%	-183.12M 26.82%	-234.63M 28.13%
depreciation and amortization	1.26M -	4.29M 241.88%	13.62M 217.28%	18.02M 32.27%	20.25M 12.38%
deferred income tax	-1.52M -	-5.61M 269.70%	39.51M 803.96%	2.32M 94.14%	4.84M 108.72%
stock based compensation	15.73M -	33.26M 111.42%	62.20M 87.01%	81.92M 31.71%	47.08M 42.53%
change in working capital	110.81M -	-336K 100.30%	4.01M 1,294.94%	-82.02M 2,142.71%	3.42M 104.17%
accounts receivables
inventory
accounts payables	1.71M -	-278K 116.27%	91K 132.73%	667K 632.97%	1.46M 119.49%
other working capital	109.10M -	-58K 100.05%	3.92M 6,865.52%	-82.68M 2,207.08%	1.96M 102.37%
other non cash items	42.57M -	11.99M 71.83%	4.62M 61.44%	-6.68M 244.53%	-4.65M 30.38%
net cash provided by operating activities	39.47M -	-160.87M 507.54%	-126.25M 21.52%	-169.56M 34.30%	-163.69M 3.46%
investments in property plant and equipment	-16.05M -	-51.48M 220.81%	-65.50M 27.24%	-24.28M 62.94%	-2.69M 88.94%
acquisitions net			673.47M -	-12.74M 101.89%
purchases of investments	-34M -	-43.45M 27.79%	-673.47M 1,450.05%	-406.32M 39.67%	-476.88M 17.37%
sales maturities of investments	238.46M -	686.32M 187.82%	617.40M 10.04%	419.05M 32.13%	663.61M 58.36%
other investing activites	-610.84M -	-864.91M 41.59%	-673.47M 22.13%	12.74M 101.89%
net cash used for investing activites	-422.43M -	-273.52M 35.25%	-121.57M 55.55%	-11.54M 90.51%	184.05M 1,694.87%
debt repayment
common stock issued	351.34M -	492.84M 40.27%	391.80M 20.50%	9.58M 97.56%	2.20M 77.03%
common stock repurchased	-185K -	-16.05M 8,575.68%		-461K -
dividends paid
other financing activites	351.16M -	476.79M 35.78%	9.44M 98.02%	1.52M 83.91%	-457K 130.09%
net cash used provided by financing activities	351.16M -	476.79M 35.78%	401.24M 15.84%	10.63M 97.35%	1.74M 83.61%
effect of forex changes on cash
net change in cash	-31.80M -	42.40M 233.32%	153.42M 261.84%	-170.46M 211.11%	22.10M 112.96%
cash at beginning of period	130.28M -	98.47M 24.41%	140.87M 43.06%	294.29M 108.91%	123.83M 57.92%
cash at end of period	98.47M -	140.87M 43.06%	294.29M 108.91%	123.83M 57.92%	145.93M 17.84%
operating cash flow	39.47M -	-160.87M 507.54%	-126.25M 21.52%	-169.56M 34.30%	-163.69M 3.46%
capital expenditure	-16.05M -	-51.48M 220.81%	-65.50M 27.24%	-24.28M 62.94%	-2.69M 88.94%
free cash flow	23.43M -	-212.35M 1,006.45%	-191.75M 9.70%	-193.83M 1.08%	-166.38M 14.16%

All numbers in (except ratios and percentages)